Post by icemandios on Aug 2, 2017 18:28:00 GMT
BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET
- Company to Also Provide Data and Development Plan Update on 4e13 vg/kg Dose of Investigational Gene Therapy Product BMN 270 for Hemophilia A
SAN RAFAEL, Calif., July 31, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 2, at 4:30 p.m. ET to discuss second quarter 2017 financial results and provide a general business update. In addition, the company will provide a data and development plan update on the 4e13 vg/kg dose of investigational gene therapy product BMN 270 for hemophilia A.
Dial-in Number
U.S. / Canada Dial-in Number: (866) 502-9859
International Dial-in Number: (574) 990-1362
Conference ID: 41574149
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 41574149
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com.
- Company to Also Provide Data and Development Plan Update on 4e13 vg/kg Dose of Investigational Gene Therapy Product BMN 270 for Hemophilia A
SAN RAFAEL, Calif., July 31, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 2, at 4:30 p.m. ET to discuss second quarter 2017 financial results and provide a general business update. In addition, the company will provide a data and development plan update on the 4e13 vg/kg dose of investigational gene therapy product BMN 270 for hemophilia A.
Dial-in Number
U.S. / Canada Dial-in Number: (866) 502-9859
International Dial-in Number: (574) 990-1362
Conference ID: 41574149
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 41574149
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com.